Use of a tacrolimus-eluting stent to inhibit neointimal hyperplasia in a porcine coronary model

Journal of Invasive Cardiology

Volumn 17, Issue 3, 2005, Pages 142-148

  Huang, Yanming ^a   Salu, Koen ^a   Wang, Lan ^a   Liu, Xiaoshun ^a   Li, Shengqiao ^a   Lorenz, Gunter ^a   Wnendt, Stephan ^a   Verbeken, Eric ^a   Bosmans, Johan ^a   Van De Werf, Frans ^a   De Scheerder, Ivan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; TACROLIMUS; BIOMATERIAL; IMMUNOSUPPRESSIVE AGENT;

ARTERY INTIMA PROLIFERATION; ARTICLE; BIOCOMPATIBILITY; CELL GROWTH; CELL VIABILITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG RELEASE; FEMALE; IN VITRO STUDY; MALE; NONHUMAN; SMOOTH MUSCLE FIBER; SWINE; ANIMAL; CELL SURVIVAL; CORONARY BLOOD VESSEL; DISEASE MODEL; IMMUNOHISTOCHEMISTRY; INTIMA; PATHOLOGY; RESTENOSIS; STENT;

ANIMALS; CELL SURVIVAL; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; MALE; PACLITAXEL; STENTS; SWINE; TACROLIMUS; TUNICA INTIMA;

EID: 18444376456     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Al Suwaidi J, Berger P, Holmes DR. Coronary artery stents. JAMA 2000;284:1826-1836.
2. Goldberg SL, Loussararian A, De Gregorio J, et al. Predictors of diffuse and aggressive intrastent restenosis. J Am Coll Cardiol 2001;37:1019-1025.
3. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996;94:1247-1254.
4. Mudra H, Regar E, Klauss V, et al. Serial follow-up after optimized ultrasound-guided deployment of Palmaz-Schatz stents. In-stent neointimal proliferation without significant reference segment response. Circulation 1997;95:363-370.
5. Reidy MA. A reassessment of endothelial injury and arterial lesion formation. Lab Invest 1985;53:513-520.
6. Ferrell M, Fuster V, Gold HK, Chesebro JH. A dilemma for the 1990s. Choosing appropriate experimental animal model for the prevention of restenosis. Circulation 1992;85:1630-1631.
7. Grewe PH, Deneke T, Machraoui A, et al. Acute and chronic tissue response to coronary stent implantation: Pathologic findings in human specimen. J Am Coll Cardiol 2000;35:157-163.
8. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52.
9. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-195.
10. De Scheerder I, Huang Y. Anti-inflammatory approach to restenosis. In Rothman MT, ed. Restenosis: Multiple strategies for stent drug delivery. London: ReMEDICA Publishing, 2001, pp13-31.
11. Kino T, Hatanaka H, Hashimoto M, et al. K-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 1987;40:1249-1255.
12. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997;54:925-975.
13. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: A phase I study in adults and children. J Am Acad Dermatol 1998;38:69-76.
14. Zabawski EJ, Costner M, Cohen JB, Cockerell CJ. Tacrolimus: Pharmacology and therapeutic uses in dermatology, Int J Dermatol 2000;39:721-727.
15. Bruijns RH, Bult H. Effects of local cytochalasin D delivery on smooth muscle cell migration and on collar-induced intimal hyperplasia in the rabbit carotid artery. Br J Pharmacol 2001;134:473-483.
16. Bonin PD, Singh JP, Gammill RB, Erickson LA. Inhibition of fibroblast and smooth muscle cell proliferation and migration in vitro by a novel aminochromone U-67154. J Vasc Res 1993;30:108-115.
17. De Scheerder IK, Wang K, Kerdsinchai P, et al. The concept of the home-made coronary stent: Experimental results and initial clinical experience. Cathet Cardiovasc Diagn 1996;39:191-196.
18. De Scheerder I, Wang K, Wilczek K, et al. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation 1997;95:1549-1553.
19. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 1992;19:267-274.
20. Farb A, Weber DK, Kolodgie FD, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002;105:2974-2980.
21. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-1697.
22. De Scheerder IK, Wilczek KL, Verbeken EV, et al. Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries. Atherosclerosis 1995;114:105-114.
23. Fontaine AB, Koelling K, Clay J, et al. Decreased platelet adherence of polymer-coated tantalum stents. J Vasc Intervent Radiol 1994;5:567-572.
24. Holmes DR, Camrud AR, Jorgenson MA, et al. Polymeric stenting in the porcine coronary artery model: Differential outcome of exogenous fibrin sleeves versus polyurethane-coated stents. J Am Coll Cardiol 1994;24:525-531.
25. Whelan DM, van der Giessen WJ, Krabbendam SC, et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000;83:338-345.
26. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): Molecular and cellular mechanisms. Ther Drug Monit 1995;17:584-591.
27. Almawi WY, Melemedjian OK. Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A. Nephrol Dial Transplant 2000;15:1916-1918.
28. Moreno PR, Bernardi VH, Lopez-Cuellar J, et al. Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation 1996;94:3098-3102.
29. Kornowski R, Hong MK, Tio FO, et al. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-230.
30. De Scheerder I, Wang K, Wilczek K, et al. Local methylprednisolone inhibition of foreign body response to coated intracoronary stents. Coron Artery Dis 1996;7:161-166.
31. Liu X, Huang Y, Hanet C, et al. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): A first-in-human multicenter pilot trial. Cathet Cardiovasc Intervent 2003;60:172-178.
32. Wieneke H, Dirsch O, Sawitowski T, et al. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Cathet Cardiovasc Intervent 2003;60:399-407.
33. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-479.
34. Drachmen DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months. J Am Coll Cardiol 2000;36:2325-2332.